More promising vaccine news poured in on Monday, with drugmaker AstraZeneca announcing its COVID-19 vaccine candidate displayed “positive high-level results” following clinical trials. The results are comparable to efficacy rates announced by fellow pharmaceutical companies Moderna and Pfizer.
The company stated in a press release that the vaccine candidate, called AZD1222, was given to thousands of volunteers in interim doses.
When given as a half dose followed by a full dose within a month, the vaccine showed an efficacy rate of 90 percent for a portion of the sample population.
When adding two full doses within a month, the efficacy rate stood at about 62 percent. The combined analysis from these two studies averaged to a 70 percent efficacy rate.
Read more at The Hill.